ArticleAddiction & health2019
The Assessment of Serum Apelin-12 Level in a Variety of Pulmonary Malignancies in Smokers.
Article in Addiction & health, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 7 citations in OpenAlex.
- Significance of Serum Apelin Levels as a Biomarker for Gastric Cancer Diagnosis.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- Review
- Melanoma Progression under Obesity: Focus on Adipokines.Cancers · 2021Review
- Study Progression of Apelin/APJ Signaling and Apela in Different Types of Cancer.Frontiers in oncology · 2021Review
- The Combined Detection of Immune Genes for Predicting the Prognosis of Patients With Non-Small Cell Lung Cancer.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundApelin has recently been considered as an adipokine secreted from visceral fat. Apelin and its receptor exist in many tissues including lung and play significant roles in many physiological and pathological activities. However, serum level of apelin-12 is unknown in smokers and in various types of lung malignancies. Therefore, the amount of this hormone in non-patient smokers and the correlation of apelin serum level with the types of lung cancer in smokers afflicted with lung cancer are evaluated in this study.
methodsThe amount of serum apelin-12 was measured in 63 patients (59 smokers and 4 non-smokers) with the variety of lung cancer and 61 age- and sex-matched controls (30 smokers and 31 non-smokers) using enzyme-linked immunosorbent assay (ELISA) kit.
findingsThe amount of serum apelin-12 in non-patient smokers (2142.20 ± 843.61 ng/l) was significantly higher than healthy non-smokers (800.39 ± 336.01 ng/l, P < 0.05), and in the variety of lung malignancies, the amount of serum apelin-12 was 2205.54 ± 187.31 ng/l in patients with squamous cell carcinoma (SCC) which was a significant increase compared to 1088.00 ± 136.52 ng/l in adenocarcinoma, 797.25 ± 88.69 ng/l in small cell carcinoma, and 1000.37 ± 62.87 ng/l in other malignancies of lung.
conclusionThe meaningful increase in apelin-12 levels of non-patient smokers can be considered as a risk factor for outbreaking of lung SCC in these people. Therefore, apelin-12 may be considered as a target in controlling lung SCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.